SOURCES:

National MS Society.

Multiple Sclerosis International Federation. “World of MS - Resources - Clinically isolated syndrome.”

McDonald, W. I, A. Compston, G. Edan, D. Goodkin, H. P Hartung, F. D Lublin, H. F McFarland, D. W Paty, C. H Polman, and S. C Reingold. “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.” Annals of neurology 50, no. 1 (2001): 121-127.

Gold, R., J. S Wolinsky, M. P Amato, and G. Comi. “Evolving expectations around early management of multiple sclerosis.” Therapeutic Advances in Neurological Disorders 3, no. 6 (2010): 351.

National Institute of Neurological Disorders and Stroke (NINDS). “Multiple Sclerosis: Hope Through Research”

Kachuck, N., and M. K Racke. “Monitoring Disease Progression: Incorporating MRI and New Modalities in Clinical Decision Making” (n.d.).

Kalb, P. D.R.C. Multiple sclerosis: The questions you have, the answers you need. Demos Health, 2008.

Crayton, H., R. A Heyman, and H. S Rossman. “A multimodal approach to managing the symptoms of multiple sclerosis.” Neurology 63, no. Issue 11, Supplement 5 (2004): S12.

Rae-Grant, A. D, N. J Eckert, S. Bartz, and J. F Reed. “Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity.” Multiple Sclerosis 5, no. 3 (1999): 179.

National MS Society. “Expert Opinion Paper: Management of MS Related Fatigue.”

Dean, L. “Comparing Drugs for Multiple Sclerosis - PubMed Health.” PubMed Health, February 11, 2011.

NAAC National Anemia Action Council. “Anemia FAQs of Symptoms, Causes, Diagnosis and Treatment.”

FDA. “U S Food and Drug Administration Home Page”

National Library of Medicine (NLM) at the National Institutes of Health (NIH). “PubMed Health”

Havrdova, E., R. Zivadinov, J. Krasensky, M. G. Dwyer, I. Novakova, O. Dolezal, V. Ticha, L. Dusek, E. Houzvickova, and J. L. Cox. “Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.” Multiple Sclerosis 15, no. 8 (2009): 965.

National Institutes of Medicine. “MedlinePlus: Drugs, Herbs and Supplements.”

Frohman, E. M, K. Brannon, M. K Racke, and K. Hawker. “Mycophenolate mofetil in multiple sclerosis.” Clinical neuropharmacology 27, no. 2 (2004): 80.

Cleveland Clinic. “Mycophenolate Mofetil (CellCept)”, n.d.

Goodin, D. S., B. G. Arnason, P. K. Coyle, E. M. Frohman, and D. W. Paty. “The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis.” Neurology 61, no. 10 (2003): 1332.

Marrie, R. A., R. Rudick, R. Horwitz, G. Cutter, T. Tyry, D. Campagnolo, and T. Vollmer. “Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.” Neurology 74, no. 13 (2010): 1041.

Hasson, J. “Is there an MS diet?” Momentum, National MS Society, Fall 2008.

Nowack, D. “Is there a diet that helps people with MS?” Momentum, National MS Society, Fall 2008.

Schwarz, S., and H. Leweling. “Multiple sclerosis and nutrition.” Multiple sclerosis 11, no. 1 (2005): 24.

Bowling, A. “So, what’s new about Vitamin D?” InsideMS, November 2006.

Munger, K. “Vitamin D intake and incidence of multiple sclerosis.” Neurology 62 (January 13, 2004): 60-5.

Brown, T. “Exercise and rehabilitation for individuals with m... [Phys Med Rehabil Clin N Am. 2005] - PubMed result.” Physical medicine and rehabilitation clinics of North America 16 (May 2005): 513-55.

National Center of Physical Activity and Disability. “Disability/Condition: Multiple Sclerosis: Designing an Exercise Program.”

Solaro C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919.

Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830-4.

Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281.

Beck RW, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581.

The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990;27(6):591.

Rudge P, et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. JNeurol Neurosurg Psychiatry. 1989;52(5):559.

Symister, Petra; Friend, Ronald. Health Psychology. 2003.  Vol 22(2), 123-129.

Affleck, Glenn; Tennen, Howard; Apter, Andrea Chang, Edward C. Optimism & pessimism: Implications for theory, research, and practice. Washington, DC, US 2001. pp. 147-168.

Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia. 2008;49(6):948.

Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis.Arch Neurol. 2004;61(4):525.

Office of Dietary Supplements: “Dietary Supplement Fact Sheet: Vitamin D.”

Pierrot-Deseilligny, C. Clinical implications of a possible role of vitamin D in multiple sclerosis J Neurol (2009) 256:1468–1479.

National MS Society: “Exercise as Part of Everyday Life.”

National MS Society: “Exercise.”

National MS Society: “Stress.”

David C Mohr, Stacey L Hart, Laura Julian, Darcy Cox, Daniel Pelletier. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ, 2004.

National MS Society: “Pregnancy and Reproductive Issues.”

National MS Society: “Optic Neuritis.”

National MS Society: “Clinically isolated syndrome (CIS).”

National MS Society: “Adherence. Starting a Disease-Modifying Therapy and Sticking with It.”

National MS Society: “Talking about Initiating and Adhering to Treatment with Injectable Disease-Modifying Agents.”

National MS Society: “The MS Disease-Modifying Medications.”

National MS Society: “Emotional Changes.”

Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(2):CD003208.

Goodkin  DE, Rudick  RA, VanderBrug Medendorp  S, Daughtry  MM, Schwetz  KM, Fischer  J, et al.  Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.  Ann Neurol.  1995;37:30–40.

Calabresi  PA, Wilterdink  JL, Rogg  JM, Mills  P, Webb  A, Whartenby  KA.  An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS.  Neurology.  2002;58:314–7.

Cohen et al. Results of the AvonexCombination Trial (ACT) in relapsing-remitting MS. Neurology 2009 Feb 10;72(6):535-41.